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8 isolates were 0.031, 0.25, 0.125 μg/mL, respectively. And the MIC50 against C. 127 parapsilosis isolates were 0.031, 0.125, 0.25 μg/mL, respectively. The GM MICs of 128 SHR8008 for C. albicans and C. parapsilosis were very low (0.037 μg/mL; 0,042 μg/mL) 129 and MIC values of SHR8008 were ≤ 0.5 μg/mL for all C. albicans (Fig. 4C ). For C. 130 albicans, SHR8008 (GM MIC=0.037 μg/mL) was 8.6-fold and 10.9-fold more potent 131 than ITC and FLC, respectively. For C. parapsilosis, SHR8008 (GM MIC=0.042 μg/mL) 132 was 5-fold and 8-fold more potent than ITC and FLC, respectively. In C. albicans and C. 133 parapsilosis isolates the MIC90 values of SHR8008 were 0.125, 1 μg/mL, respectively. (Fig. 5) . With the 50% inhibition endpoint, the SHR8008 MIC50, MIC90, and GM
140
MIC values were 0.016, 0.125, 0.024 μg/mL, respectively. Based on GM MIC, SHR8008 141 (GM MIC=0.024 μg/mL) was 21.7-fold and 104.5-fold more potent than ITC and FLC, 142 respectively, and the differences between SHR8008 and FLC were statistically significant.
143
The MIC distributions for SHR8008, ITC and FLC against the C. neoformans isolates are 
